Correction to: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT (Bone Marrow Transplantation, (2024), 59, 6, (832-837), 10.1038/s41409-024-02251-0)

Anna Sureda; Paul A. Carpenter; Andrea Bacigalupo; Vijaya Raj Bhatt; Josu de la Fuente; Aloysius Ho; Leslie Kean; Jong Wook Lee; Isabel Sánchez-Ortega; Bipin N. Savani; Johannes Schetelig; Edward A. Stadtmauer; Yoshiyuki Takahashi; Yoshiko Atsuta; John Koreth; Nicolaus Kröger; Per Ljungman; Shinichiro Okamoto; Uday Popat; Robert Soiffer; Heather E. Stefanski; Mohamed A. Kharfan-Dabaja

doi:10.1038/s41409-024-02336-w

Correction to: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT (Bone Marrow Transplantation, (2024), 59, 6, (832-837), 10.1038/s41409-024-02251-0)

Anna Sureda
, Paul A. Carpenter
, Andrea Bacigalupo
, Vijaya Raj Bhatt
, Josu de la Fuente
, Aloysius Ho
, Leslie Kean
, Jong Wook Lee
, Isabel Sánchez-Ortega
, Bipin N. Savani
, Johannes Schetelig
, Edward A. Stadtmauer
, Yoshiyuki Takahashi
, Yoshiko Atsuta
, John Koreth
, Nicolaus Kröger
, Per Ljungman
, Shinichiro Okamoto
, Uday Popat
, Robert Soiffer

Heather E. Stefanski, Mohamed A. Kharfan-Dabaja

Division of Hematology

University of Barcelona
Fred Hutchinson Cancer Research Center
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
University of Nebraska Medical Center
Imperial College Healthcare NHS Trust
Imperial College London
National Cancer Centre
Boston Children's Hospital
Dana-Farber Cancer Institute
EBMT Executive Office
Vanderbilt University
Technische Universität Dresden
University of Pennsylvania
Nagoya University
The Japanese Data Center for Hematopoietic Cell Transplantation
Aichi Medical University
University of Hamburg
Karolinska Institutet
Keio University
University of Texas MD Anderson Cancer Center
National Marrow Donor Program
Mayo Clinic Jacksonville, FL

Research output: Contribution to journal › Comment/debate

4 Scopus citations

Abstract

Correction to: Bone Marrow Transplantationhttps://doi.org/10.1038/s41409-024-02251-0, published online 5 March 2024 The Funding information section was missing from this article and should have read: CIBMTR is supported primarily by the Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); 75R60222C00011 from the Health Resources and Services Administration (HRSA); and N00014-23-1-2057 and N00014-24-1-2057 from the Office of Naval Research. Support is also provided by the Medical College of Wisconsin, NMDP, Gateway for Cancer Research, Pediatric Transplantation and Cellular Therapy Consortium and from the following commercial entities: AbbVie; Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies Corporation; ADC Therapeutics; Adienne SA; Alexion; Allogene; AlloVir, Inc.; Amgen, Inc.; Astellas Pharma US; AstraZeneca; Atara Biotherapeutics; BeiGene; BioLineRX; Blue Spark Technologies; bluebird bio, inc.; Blueprint Medicines; Bristol Myers Squibb Co.; CareDx Inc.; CSL Behring; CytoSen Therapeutics, Inc.; DKMS; Eurofins Viracor, DBA Eurofins Transplant Diagnostics; Gamida-Cell, Ltd.; Gift of Life Biologics; Gift of Life Marrow Registry; GlaxoSmithKline; HistoGenetics; Incyte Corporation; Iovance; Janssen Research & Development, LLC; Janssen/Johnson & Johnson; Jasper Therapeutics; Jazz Pharmaceuticals, Inc.; Karius; Kashi Clinical Laboratories; Kiadis Pharma; Kite, a Gilead Company; Kyowa Kirin; Labcorp; Legend Biotech; Mallinckrodt Pharmaceuticals; Med Learning Group; Merck & Co.; Mesoblast; Millennium, the Takeda Oncology Co.; Miller Pharmacal Group, Inc.; Miltenyi Biotec, Inc.; MorphoSys; MSA-EDITLife; Neovii Pharmaceuticals AG; Novartis Pharmaceuticals Corporation; Omeros Corporation; OptumHealth; Orca Biosystems, Inc.; OriGen BioMedical; Ossium Health, Inc.; Pfizer, Inc.; Pharmacyclics, LLC, An AbbVie Company; PPD Development, LP; REGiMMUNE; Registry Partners; Rigel Pharmaceuticals; Sanofi; Sarah Cannon; Seagen Inc.; Sobi, Inc.; Stemcell Technologies; Stemline Technologies; STEMSOFT; Takeda Pharmaceuticals; Talaris Therapeutics; Vertex Pharmaceuticals; Vor Biopharma Inc.; WellSky; Xenikos BV. The original article has been corrected.

Original language	English
Pages (from-to)	1335
Number of pages	1
Journal	Bone Marrow Transplantation
Volume	59
Issue number	9
DOIs	https://doi.org/10.1038/s41409-024-02336-w
State	Published - Sep 2024

Bibliographical note

Publisher Copyright:
© The Author(s) 2024.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/s41409-024-02336-w

Fingerprint

Dive into the research topics of 'Correction to: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT (Bone Marrow Transplantation, (2024), 59, 6, (832-837), 10.1038/s41409-024-02251-0)'. Together they form a unique fingerprint.

Cite this

Sureda, A., Carpenter, P. A., Bacigalupo, A., Bhatt, V. R., de la Fuente, J., Ho, A., Kean, L., Lee, J. W., Sánchez-Ortega, I., Savani, B. N., Schetelig, J., Stadtmauer, E. A., Takahashi, Y., Atsuta, Y., Koreth, J., Kröger, N., Ljungman, P., Okamoto, S., Popat, U., ... Kharfan-Dabaja, M. A. (2024). Correction to: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT (Bone Marrow Transplantation, (2024), 59, 6, (832-837), 10.1038/s41409-024-02251-0). Bone Marrow Transplantation, 59(9), 1335. https://doi.org/10.1038/s41409-024-02336-w

Sureda, Anna ; Carpenter, Paul A. ; Bacigalupo, Andrea et al. / Correction to : Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT (Bone Marrow Transplantation, (2024), 59, 6, (832-837), 10.1038/s41409-024-02251-0). In: Bone Marrow Transplantation. 2024 ; Vol. 59, No. 9. pp. 1335.

@article{d008e51a102d4b359f6c9fcba85273ab,

title = "Correction to: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT (Bone Marrow Transplantation, (2024), 59, 6, (832-837), 10.1038/s41409-024-02251-0)",

abstract = "Correction to: Bone Marrow Transplantationhttps://doi.org/10.1038/s41409-024-02251-0, published online 5 March 2024 The Funding information section was missing from this article and should have read: CIBMTR is supported primarily by the Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); 75R60222C00011 from the Health Resources and Services Administration (HRSA); and N00014-23-1-2057 and N00014-24-1-2057 from the Office of Naval Research. Support is also provided by the Medical College of Wisconsin, NMDP, Gateway for Cancer Research, Pediatric Transplantation and Cellular Therapy Consortium and from the following commercial entities: AbbVie; Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies Corporation; ADC Therapeutics; Adienne SA; Alexion; Allogene; AlloVir, Inc.; Amgen, Inc.; Astellas Pharma US; AstraZeneca; Atara Biotherapeutics; BeiGene; BioLineRX; Blue Spark Technologies; bluebird bio, inc.; Blueprint Medicines; Bristol Myers Squibb Co.; CareDx Inc.; CSL Behring; CytoSen Therapeutics, Inc.; DKMS; Eurofins Viracor, DBA Eurofins Transplant Diagnostics; Gamida-Cell, Ltd.; Gift of Life Biologics; Gift of Life Marrow Registry; GlaxoSmithKline; HistoGenetics; Incyte Corporation; Iovance; Janssen Research \& Development, LLC; Janssen/Johnson \& Johnson; Jasper Therapeutics; Jazz Pharmaceuticals, Inc.; Karius; Kashi Clinical Laboratories; Kiadis Pharma; Kite, a Gilead Company; Kyowa Kirin; Labcorp; Legend Biotech; Mallinckrodt Pharmaceuticals; Med Learning Group; Merck \& Co.; Mesoblast; Millennium, the Takeda Oncology Co.; Miller Pharmacal Group, Inc.; Miltenyi Biotec, Inc.; MorphoSys; MSA-EDITLife; Neovii Pharmaceuticals AG; Novartis Pharmaceuticals Corporation; Omeros Corporation; OptumHealth; Orca Biosystems, Inc.; OriGen BioMedical; Ossium Health, Inc.; Pfizer, Inc.; Pharmacyclics, LLC, An AbbVie Company; PPD Development, LP; REGiMMUNE; Registry Partners; Rigel Pharmaceuticals; Sanofi; Sarah Cannon; Seagen Inc.; Sobi, Inc.; Stemcell Technologies; Stemline Technologies; STEMSOFT; Takeda Pharmaceuticals; Talaris Therapeutics; Vertex Pharmaceuticals; Vor Biopharma Inc.; WellSky; Xenikos BV. The original article has been corrected.",

author = "Anna Sureda and Carpenter, \{Paul A.\} and Andrea Bacigalupo and Bhatt, \{Vijaya Raj\} and \{de la Fuente\}, Josu and Aloysius Ho and Leslie Kean and Lee, \{Jong Wook\} and Isabel S{\'a}nchez-Ortega and Savani, \{Bipin N.\} and Johannes Schetelig and Stadtmauer, \{Edward A.\} and Yoshiyuki Takahashi and Yoshiko Atsuta and John Koreth and Nicolaus Kr{\"o}ger and Per Ljungman and Shinichiro Okamoto and Uday Popat and Robert Soiffer and Stefanski, \{Heather E.\} and Kharfan-Dabaja, \{Mohamed A.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = sep,

doi = "10.1038/s41409-024-02336-w",

language = "English",

volume = "59",

pages = "1335",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Springer Nature",

number = "9",

}

Sureda, A, Carpenter, PA, Bacigalupo, A, Bhatt, VR, de la Fuente, J, Ho, A, Kean, L, Lee, JW, Sánchez-Ortega, I, Savani, BN, Schetelig, J, Stadtmauer, EA, Takahashi, Y, Atsuta, Y, Koreth, J, Kröger, N, Ljungman, P, Okamoto, S, Popat, U, Soiffer, R, Stefanski, HE & Kharfan-Dabaja, MA 2024, 'Correction to: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT (Bone Marrow Transplantation, (2024), 59, 6, (832-837), 10.1038/s41409-024-02251-0)', Bone Marrow Transplantation, vol. 59, no. 9, pp. 1335. https://doi.org/10.1038/s41409-024-02336-w

Correction to: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT (Bone Marrow Transplantation, (2024), 59, 6, (832-837), 10.1038/s41409-024-02251-0). / Sureda, Anna; Carpenter, Paul A.; Bacigalupo, Andrea et al.
In: Bone Marrow Transplantation, Vol. 59, No. 9, 09.2024, p. 1335.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction to

T2 - Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT (Bone Marrow Transplantation, (2024), 59, 6, (832-837), 10.1038/s41409-024-02251-0)

AU - Sureda, Anna

AU - Carpenter, Paul A.

AU - Bacigalupo, Andrea

AU - Bhatt, Vijaya Raj

AU - de la Fuente, Josu

AU - Ho, Aloysius

AU - Kean, Leslie

AU - Lee, Jong Wook

AU - Sánchez-Ortega, Isabel

AU - Savani, Bipin N.

AU - Schetelig, Johannes

AU - Stadtmauer, Edward A.

AU - Takahashi, Yoshiyuki

AU - Atsuta, Yoshiko

AU - Koreth, John

AU - Kröger, Nicolaus

AU - Ljungman, Per

AU - Okamoto, Shinichiro

AU - Popat, Uday

AU - Soiffer, Robert

AU - Stefanski, Heather E.

AU - Kharfan-Dabaja, Mohamed A.

PY - 2024/9

Y1 - 2024/9

N2 - Correction to: Bone Marrow Transplantationhttps://doi.org/10.1038/s41409-024-02251-0, published online 5 March 2024 The Funding information section was missing from this article and should have read: CIBMTR is supported primarily by the Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); 75R60222C00011 from the Health Resources and Services Administration (HRSA); and N00014-23-1-2057 and N00014-24-1-2057 from the Office of Naval Research. Support is also provided by the Medical College of Wisconsin, NMDP, Gateway for Cancer Research, Pediatric Transplantation and Cellular Therapy Consortium and from the following commercial entities: AbbVie; Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies Corporation; ADC Therapeutics; Adienne SA; Alexion; Allogene; AlloVir, Inc.; Amgen, Inc.; Astellas Pharma US; AstraZeneca; Atara Biotherapeutics; BeiGene; BioLineRX; Blue Spark Technologies; bluebird bio, inc.; Blueprint Medicines; Bristol Myers Squibb Co.; CareDx Inc.; CSL Behring; CytoSen Therapeutics, Inc.; DKMS; Eurofins Viracor, DBA Eurofins Transplant Diagnostics; Gamida-Cell, Ltd.; Gift of Life Biologics; Gift of Life Marrow Registry; GlaxoSmithKline; HistoGenetics; Incyte Corporation; Iovance; Janssen Research & Development, LLC; Janssen/Johnson & Johnson; Jasper Therapeutics; Jazz Pharmaceuticals, Inc.; Karius; Kashi Clinical Laboratories; Kiadis Pharma; Kite, a Gilead Company; Kyowa Kirin; Labcorp; Legend Biotech; Mallinckrodt Pharmaceuticals; Med Learning Group; Merck & Co.; Mesoblast; Millennium, the Takeda Oncology Co.; Miller Pharmacal Group, Inc.; Miltenyi Biotec, Inc.; MorphoSys; MSA-EDITLife; Neovii Pharmaceuticals AG; Novartis Pharmaceuticals Corporation; Omeros Corporation; OptumHealth; Orca Biosystems, Inc.; OriGen BioMedical; Ossium Health, Inc.; Pfizer, Inc.; Pharmacyclics, LLC, An AbbVie Company; PPD Development, LP; REGiMMUNE; Registry Partners; Rigel Pharmaceuticals; Sanofi; Sarah Cannon; Seagen Inc.; Sobi, Inc.; Stemcell Technologies; Stemline Technologies; STEMSOFT; Takeda Pharmaceuticals; Talaris Therapeutics; Vertex Pharmaceuticals; Vor Biopharma Inc.; WellSky; Xenikos BV. The original article has been corrected.

AB - Correction to: Bone Marrow Transplantationhttps://doi.org/10.1038/s41409-024-02251-0, published online 5 March 2024 The Funding information section was missing from this article and should have read: CIBMTR is supported primarily by the Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); 75R60222C00011 from the Health Resources and Services Administration (HRSA); and N00014-23-1-2057 and N00014-24-1-2057 from the Office of Naval Research. Support is also provided by the Medical College of Wisconsin, NMDP, Gateway for Cancer Research, Pediatric Transplantation and Cellular Therapy Consortium and from the following commercial entities: AbbVie; Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies Corporation; ADC Therapeutics; Adienne SA; Alexion; Allogene; AlloVir, Inc.; Amgen, Inc.; Astellas Pharma US; AstraZeneca; Atara Biotherapeutics; BeiGene; BioLineRX; Blue Spark Technologies; bluebird bio, inc.; Blueprint Medicines; Bristol Myers Squibb Co.; CareDx Inc.; CSL Behring; CytoSen Therapeutics, Inc.; DKMS; Eurofins Viracor, DBA Eurofins Transplant Diagnostics; Gamida-Cell, Ltd.; Gift of Life Biologics; Gift of Life Marrow Registry; GlaxoSmithKline; HistoGenetics; Incyte Corporation; Iovance; Janssen Research & Development, LLC; Janssen/Johnson & Johnson; Jasper Therapeutics; Jazz Pharmaceuticals, Inc.; Karius; Kashi Clinical Laboratories; Kiadis Pharma; Kite, a Gilead Company; Kyowa Kirin; Labcorp; Legend Biotech; Mallinckrodt Pharmaceuticals; Med Learning Group; Merck & Co.; Mesoblast; Millennium, the Takeda Oncology Co.; Miller Pharmacal Group, Inc.; Miltenyi Biotec, Inc.; MorphoSys; MSA-EDITLife; Neovii Pharmaceuticals AG; Novartis Pharmaceuticals Corporation; Omeros Corporation; OptumHealth; Orca Biosystems, Inc.; OriGen BioMedical; Ossium Health, Inc.; Pfizer, Inc.; Pharmacyclics, LLC, An AbbVie Company; PPD Development, LP; REGiMMUNE; Registry Partners; Rigel Pharmaceuticals; Sanofi; Sarah Cannon; Seagen Inc.; Sobi, Inc.; Stemcell Technologies; Stemline Technologies; STEMSOFT; Takeda Pharmaceuticals; Talaris Therapeutics; Vertex Pharmaceuticals; Vor Biopharma Inc.; WellSky; Xenikos BV. The original article has been corrected.

UR - https://www.scopus.com/pages/publications/85196521768

U2 - 10.1038/s41409-024-02336-w

DO - 10.1038/s41409-024-02336-w

M3 - Comment/debate

AN - SCOPUS:85196521768

SN - 0268-3369

VL - 59

SP - 1335

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 9

ER -

Sureda A, Carpenter PA, Bacigalupo A, Bhatt VR, de la Fuente J, Ho A et al. Correction to: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT (Bone Marrow Transplantation, (2024), 59, 6, (832-837), 10.1038/s41409-024-02251-0). Bone Marrow Transplantation. 2024 Sep;59(9):1335. doi: 10.1038/s41409-024-02336-w